KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting

Antonio Russo, Valerio Gristina, Umberto Malapelle, Elena Vigliar, Claudio Bellevicine, Caterina De Luca, Roberta Sgariglia, Pasquale Pisapia, Mariantonia Nacchio, Ilaria Migliatico, Eduardo Clery, Francesco Pepe, Giancarlo Troncone, Lorenza Greco

Risultato della ricerca: Articlepeer review

7 Citazioni (Scopus)

Abstract

In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe® panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes included in the SiRe® panel, such as epidermal growth factor receptor (EGFR) and v-Raf murine sarcoma viral oncogene homolog B (BRAF). Exon 2 p.G12C was the most common detected mutation (13/36, 36.1%). In conclusion, our data update and confirm that SiRe® NGS panel represents a robust analytical tool to assess KRAS mutational status on circulating tumor DNA. Further investigation is required to design more cost-effective diagnostic algorithms to harmonize clinical relevant biomarker testing on tissue and blood in advanced stage NSCLC clinical practice.
Lingua originaleEnglish
pagine (da-a)3836-3843
Numero di pagine8
RivistaJournal of Thoracic Disease
Volume12
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cita questo